Peritoneal cancer vaccine - AVAX Technologies
Latest Information Update: 17 Mar 2008
At a glance
- Originator AVAX Technologies
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Peritoneal cancer
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 17 Mar 2008 Discontinued - Phase-I for Peritoneal cancer in France (Parenteral)
- 10 Aug 2005 Phase-I clinical trials in Peritoneal cancer in France (Parenteral)